. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Int J Obes (Lond). 2021 Nov 22;46(3):555–563. doi: 10.1038/s41366-021-01019-6

Table 3.

Documented Adverse Events

	Incidence (n=304 per year)	Treatment Suspended	Adverse Events
Total	68 (22.4%)	26 (8.6%)	Treatment was suspended in 9% of the subjects due to side effects. None were severe enough to prompt hospitalization.
Phentermine/ Topiramate-ER	32/155 (20.6%)	10 (6.4%)	Insomnia (4.3%), paresthesia (3.6%). Dry mouth (2.9%), constipation (1.4%), Nausea (2.2%), Restlessness (1.4%), Anxiety (2.9), Others (3.6%)
Liraglutide	19/80 (23.7%)	4 (5.0%)	Nausea (14.3%), Diarrhea (7.1%) Vomiting (4.3%), dyspepsia (2.9%) Constipation (1.4%), mood change (1.4%), others (7.1%)
Lorcaserin	2/19 (10.5%)	2 (10.5%)	Dizziness (10.5%)
Bupropion/Naltrexone-SR	15/50 (30.0%)	9 (18.0%)	Nausea (18.8%) Mood changes (6.3%), Vomiting (2%), Constipation (4.1%). Other (10.4%)